1 / 24

Laboratory of Method Development

Laboratory of Method Development. Division of Viral Products Office of Vaccines Research and Review. LMD Mission Statement. To conduct research leading to new concepts and methods for quality control and evaluation of existing and new viral vaccines and other biologicals.

pink
Download Presentation

Laboratory of Method Development

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Laboratory of Method Development Division of Viral Products Office of Vaccines Research and Review VRBPAC meeting

  2. LMD Mission Statement To conduct research leading to new concepts and methods for quality control and evaluation of existing and new viral vaccines and other biologicals VRBPAC meeting

  3. LMD Research Programs • Chumakov: Evaluation of safety and potency of viral vaccines based on analysis of molecular consistency (Z01 BK 08013-03) • Chizhikov: Microarray-Based Evaluation of Purity and Safety of Biological Products (Z01 BK 08014-03) • Rubin: Developing tests to evaluate virus vaccine safety for the nervous system (Z01 BK 02023-03) VRBPAC meeting

  4. LMD Staff VRBPAC meeting

  5. Scope of Regulatory Responsibilities • Poliovirus vaccine and combinations • Mumps, Measles, Rubella, (Varicella) • Lot release of IPV, MMR, Gardasil® • QC of vaccines under licensure • IND and BLA related to new viral vaccines VRBPAC meeting

  6. International Activities • Advising WHO on vaccines issues • International guidances / recommendations • Validation of reference materials • International Collaborative studies • Biotechnology Engagement Program VRBPAC meeting

  7. Neuropathogenesis Team Steven Rubin, M.Sc. Acting Principal Investigator Tahir Malik, Ph.D., Staff Scientist Christian Sauder, PhD., Visiting Associate Cheryl Zhang, PhD, ORISE Fellow Malen Link, PhD, ORISE Fellow Laura Nerret, B.S., ORISE Fellow VRBPAC meeting

  8. Neuropathogenesis Team Overview • Performs research on viral vaccines associated with adverse events in the central nervous system • Pre-clinical neurovirulence safety assays • Mumps virus vaccines • Influenza virus vaccines • Vaccinia virus-based smallpox vaccines • Molecular basis of virus neurovirulence • Mumps virus • Influenza virus • Serves as a unique neuropathogenesis resource for CBER • Since the team represents one of only two active mumps virus research programs in the country, it serves as the agency’s expert on issues of mumps vaccine safety and efficacy VRBPAC meeting

  9. Recent Research Accomplishments • Mumps Virus • Leading a WHO effort to perform a large scale formal validation effort to support use of a rat-based test, developed in our laboratory, for assessing the neurological safety of new candidate mumps virus vaccines (to replace the monkey neurovirulence safety test) • Established a primary neuronal cell culture system capable of differentiating neurotoxic from non-neurotoxic mumps virus strains • Developed infectious mumps virus cDNA clones for evaluating the role of specific virus genes/proteins in mumps virus neurotropism and neurotoxicity. • Established a standardized mumps virus neutralization assay for evaluation of mumps immunity with suggested surrogate endpoints for protection • Participating member of an interagency investigation of the 2006 mumps virus epidemic and provided key data demonstrating continued vaccine efficacy and data supporting an update to the ACIP recommendations for the control and elimination of mumps to include two doses of mumps-containing vaccine instead of one for documentation of immunity VRBPAC meeting

  10. Recent Research Accomplishments • Influenza Virus • Developed a rat-based test for assessing the neurological safety of new candidate influenza virus vaccines • Established a plasmid DNA transfection system for the rescue of infectious influenza A virus to aid in the study of virus neurotropism and neurotoxicity • Vaccinia Virus • Developed a rat-based test for assessing the neurological safety of new candidate vaccinia virus-based smallpox vaccines VRBPAC meeting

  11. Microarray team Vladimir Chizhikov, PhD Principal Investigator • Dmitriy Volokhov, PhD Postdoctoral Fellow • Hyesuk Kong, PhD Postdoctoral Fellow VRBPAC meeting

  12. MICROARRAY-BASED EVALUATION OF PURITY AND SAFETY OF BIOLOGICAL PRODUCTS • Development and Improvement of Microarray Methods • Genotyping of a number of human and animal pathogens • Product Safety and Purity • Detection of extraneous agents (mycoplasma) VRBPAC meeting

  13. Advanced microarray substrates and protocols Not-fluorescent detection (nano-gold particles) Lab-on-Chip (collaboration with CDRH) Drug-resistance of M. tuberculosis (in collaboration with JHU) Genotyping of measles isolates (in collaboration with JHU) Genotyping of VZV isolates (in collaboration with CDC) P and G genotyping of rotaviruses (in collaboration with NIAID) Detection of bioterrorism pathogens in blood (in collaboration with OBRR) Detection and analysis of food-borne pathogens (in collaboration with CDRH, CFSAN) Development and Improvement of Microarray Methods Technical approaches Biological models VRBPAC meeting

  14. Main Accomplishments (2003-2007): • Establishment of FDA collection of mycoplasmas (>200 species) • Genetic analysis of the 16S-23S Intergenic spaces, potential marker for identification of mycoplasma species • Development and evaluation of a PCR/microarray assay based on nano-gold particle technology for detection identification of Mollicutes species. • Development of a cell culture-based method for biological enrichment of mycoplasma contaminants that allows for significant increase of the sensitivity of mycoplasma detection and three-fold reduction of the mycoplasma testing time. • Development and evaluation of novel microarrays for detection and analysis of important human pathogens and their virulence factors (genotyping of Clostridium perfringens toxins, screening new mutations in the structural region West Nile virus genome, identification of G and P genotypes of rotaviruses, analysis of multiple staphylococcal enterotoxin genes, and detection and analysis of bioterrorism pathogens in blood et al.) VRBPAC meeting

  15. Productivity (2003-2007): • 2 patents (together with ATCC and OBRR/FDA) • 24 publications in peer-reviewed scientific journals • 2 manuscripts in preparation • 4 invited talks including 1st International Mycosafe Symposium, April 2007 (Austria) • Several poster presentations on different international, national and FDA scientific meetings VRBPAC meeting

  16. Molecular consistency of viral vaccines • Eugenia Dragunsky, MD, PhD Staff Scientist • Gennady Rezapkin, PhD Staff Scientist • Majid Laassri, PhD Visiting Associate • Joan Enterline, BA Biologist • Monica Parker, BS Biologist • Alexander Neverov, PhD Postdoctoral Fellow • Alexander Ivanov, MD, PhD, DSci Postdoctoral Fellow (resigned 11-07) • Elena Cherkasova, PhD Postdoctoral Fellow (resigned 05-07) Konstantin Chumakov, PhD Principal investigator VRBPAC meeting

  17. Principal directions • Oral polio vaccine • Inactivated polio vaccine • Flavivirus recombinant vaccines • Influenza vaccine • Microarray methods for genotyping of viruses (Orthopox, Herpes viruses) • Molecular consistency of cell substrates (Vero cells) VRBPAC meeting

  18. Oral poliovirus vaccine • Tg mouse test for neurovirulence of OPV • Molecular basis of neurovirulence and interactions with host immune system • Genetic stability of OPV • In vitro studies • Clinical studies • Evolution of vaccine-derived polioviruses • Genomic evolution • Antigenic drift VRBPAC meeting

  19. Advanced Immunochemical Methods • Block-ELISA procedure • Epitope profiling • Paratope profiling VRBPAC meeting

  20. Inactivated Polio Vaccine • Evaluation of Sabin IPV • Combination vaccines • Transgenic mouse immunization / challenge protection test • Effect of novel adjuvants • Alternative routes of administration VRBPAC meeting

  21. Flavivirus vaccines • West Nile / Dengue 4 chimeras • TBE (Langat) / Dengue 4 chimeras • Microarray analysis of genetic stability VRBPAC meeting

  22. Seasonal Influenza Vaccines • Microarray method for rapid genotyping of genomic segments of reassortant vaccine strains • Influenza B • Influenza A VRBPAC meeting

  23. Genotyping of Orthopox and Herpes viruses • Microarray - based method • DARPA grant • BTEP-sponsored collaboration VRBPAC meeting

  24. Molecular Consistency of Cell Substrates • Tumorigenicity of Vero cells • Surrogate markers of tumorigenicity • mitochondrial DNA analysis • microarray gene expression data • proteomics • Markers of cell culture confluence • microarray analysis VRBPAC meeting

More Related